Prostate cancer is a common malignant tumor in the male urinary system. In some patients with prostate issues, there may be an increase in the carcinoembryonic antigen index in blood tests, but not all patients will exhibit this marker increase. Most prostate cancer patients will show an increase in the prostate-specific antigen (PSA) in blood tests, or there may be abnormal ratios of free PSA to bound PSA. Carcinoembryonic antigen and prostate-specific antigen are tumor markers for prostate cancer, but they only provide auxiliary value for diagnosis and do have some evaluative value regarding the effectiveness of anti-tumor treatment. Additionally, they can serve as a monitor for the condition of prostate cancer. Clinically, to confirm a diagnosis of prostate cancer, it is necessary to rely on the results of pathological tissue obtained through biopsy.